Videos

REVIEW UroToday

Pivot-006 Trial TT

Search

PIVOT-006: Phase 3 Trial Comparing Oncolytic Virus Creto vs Observation for Intermediate-Risk NMIBC - Robert Svatek Details Sam Chang hosts Rob Svatek who discusses the PIVOT-006 trial. This phase three trial targets intermediate-risk, non-muscle invasive bladder cancer, comparing a novel therapy, Cretostimogene grenadenorepvec (Creto), against observation. The goal is to enroll 364 patients over 30 months to demonstrate a 10% improvement in recurrence-free survival. The trial focuses on patients who do not qualify as...
Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson Details Mark Tyson presents results from the BOND-003 study, evaluating the efficacy of cretostimogene grenadenorepvec monotherapy in treating BCG-unresponsive non-muscle-invasive bladder cancer. Cretostimogene, an oncolytic adenovirus, selectively targets and destroys cancer cells while sparing normal tissue and boosting antitumor immunity. The phase III study reported a 75.2% complete response rate, wit...
Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua Details Sam Chang converses with Trinity Bivalacqua about treatments in non-muscle invasive bladder cancer, focusing on Cretostimogene grenadenorepvec (Creto), an oncolytic adenovirus, CG0070. Dr. Bivalacqua discusses trials exploring Creto's efficacy in managing BCG-unresponsive CIS, emphasizing its dual mechanism of action: direct tumor lysis and immune system activation. Initial results from the BOND-0...
PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson Details Ashish Kamat and Mark Tyson discuss the currently enrolling PIVOT-006 study. Dr. Tyson discusses cretostimogene grenadenorepvec, a conditionally replicating oncolytic adenovirus designed for cancer cell destruction and immunotherapeutic effects. Highlighting four pivotal studies demonstrating the agent's efficacy, especially in BCG unresponsive populations, Dr. Tyson outlines the development of in...
BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson Details Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an oncolytic adenovirus, selectively infects and kills cancer cells while sparing normal tissue and induces antitumor immunity. The phase 3 study showed a 75.7% complete response at any time point, with 7...
Cretostimogene Grenadenorepvec Therapy Aims to Fill an Unmet Need in the Bladder Cancer Armamentarium - Robert Svatek Details Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic virus targeting cells with retinoblastoma pathway defects, common in cancer cells. This treatment, when instilled in the bladder, prompts immune cells to destroy cancer cells. Highlighted are several key trials: CORE-00...
Gene Therapy for Non-muscle Invasive Bladder Cancer - Roger Li Details In this conversation, Ashish Kamat and Roger Li discuss gene therapy in the context of non-muscle invasive bladder cancer that is unresponsive to BCG treatment. Dr. Li discusses two gene therapy treatments, Adstiladrin and CG0070, and presents promising results from a Phase 2 trial combining CG0070 with pembrolizumab. Dr. Li also discusses the BOND3 study, which is a Phase 3 monotherapy trial and...